Pemetrexed combination therapy in the treatment of non-small cell lung cancer.

摘要: Until recently, the treatment of non-small cell lung cancer (NSCLC) was limited to cisplatin combinations, including a small number cytotoxic drugs. More combinations with taxanes and gemcitabine have slightly improved outcome. However, when literature is revisited, it can be realized that older drugs such as nitrogen mustard some degree activity in NSCLC, traditionally considered chemoresistant tumor. are mostly ineffective used single agents, 5-fluorouracil (5-FU), significant combined patients NSCLC. 5-FU constitutes backbone chemotherapy for colorectal patients. equally interesting because permits investigation thymidylate synthase (TS) levels genetic target predicting response survival. The assessment TS ERCC1 marker resistance leading customized chemotherapy. possibility discriminating particularly attractive choosing between non-cisplatin We reviewed phase I II studies pemetrexed rate approximately 20% single-agent 40% combination cisplatin. This has mild moderate toxicity. Other synergistic should explored include gemcitabine, CPT-11, docetaxel, carboplatin, or oxaliplatin. In future, pharmacogenomically oriented trials undertaken based on accumulated evidence several markers, ERCC1, beta-tubulin mutations, loss heterozygosity region enzyme ribonucleotide reductase, predict cisplatin, taxanes, respectively. Mechanisms need investigated, potential role messenger RNA. summary, emerged promising new drug arsenal treatments